**Core Concept**
Apixaban is a direct oral anticoagulant (DOAC) that selectively inhibits the activity of coagulation factor Xa, a key enzyme in the coagulation cascade. This inhibition prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and clot formation.

**Why the Correct Answer is Right**
Apixaban binds to and inhibits the activity of factor Xa, which is a critical step in the coagulation cascade. Factor Xa is responsible for the conversion of prothrombin to thrombin, and this process is essential for clot formation. By inhibiting factor Xa, apixaban reduces the risk of thrombotic events, such as deep vein thrombosis and pulmonary embolism. This mechanism of action is distinct from other anticoagulants, such as warfarin, which inhibit vitamin K-dependent clotting factors.

**Why Each Wrong Option is Incorrect**
**Option A:** Inhibiting TNF alpha is a mechanism of action for biologic agents, such as etanercept and infliximab, used in the treatment of autoimmune diseases, not for anticoagulation.
**Option C:** Inhibiting platelet aggregation is a mechanism of action for antiplatelet agents, such as aspirin and clopidogrel, which prevent platelet activation and aggregation, but do not directly inhibit the coagulation cascade.
**Option D:** Activating plasminogen is a mechanism of action for fibrinolytic agents, such as streptokinase and alteplase, which dissolve existing clots, but do not prevent new clot formation.

**Clinical Pearl / High-Yield Fact**
Apixaban has a predictable pharmacokinetic profile and does not require routine monitoring of coagulation tests, unlike warfarin, making it a convenient option for patients requiring long-term anticoagulation.

✓ Correct Answer: B. Inhibiting coagulation factor Xa